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Ana Paula Bernardo1,3,4*, José C Oliveira2, Olívia Santos1, Maria J Carvalho1, António Cabrita1
and Anabela Rodrigues1,3Abstract
Background: Hepatocyte growth factor (HGF) counteracts peritoneal fibrosis in animal models and in-vitro studies, but
no study explored effluent HGF in peritoneal dialysis (PD) patients with ultrafiltration failure (UFF). Our aim was to assess
the relationship between effluent HGF with UF profile, free water transport (FWT) and small-solute transport.
Methods: We performed 4-hour, 3.86% PET with additional UF measurement at 60 minutes in 68 PD patients.
MTACcreatinine, FWT, small-pore ultrafiltration, and effluent HGF were quantified.
Results: Effluent HGF negatively correlated with UF (r = −0.80, p = 0.009) and FWT (r = −0.69, p = 0.04). Patients with UFF
had higher dialysate HGF (103 pg/mL vs 77 pg/mL, p = 0.018) and, although not statistically significant, those with FWT
compromise had also higher dialysate HGF compared with subgroup of UFF without FWT compromise (104 pg/mL vs
88 pg/mL, p = 0.08). FWT≤ 45% without clinical UFF was documented in some patients who also had increased effluent
HGF.
Conclusions: Dialysate HGF concentration is significantly higher among patients with UFF, specially, if FWT is impaired,
being a sign of peritoneal membrane deterioration.
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Ultrafiltration failure (UFF) is still a challenging complica-
tion of peritoneal dialysis and its prevalence increases with
time on PD [1-3]. In long-term patients, UFF is more se-
vere and often associated with free water transport (FWT)
compromise [4-6]. The two-in-one peritoneal equilibra-
tion test allows simultaneous quantification of FWT and
small pore ultrafiltration, being a simple method for timely
detection of membrane failure, as we previously reported
[7]. Since it is known that increased submesothelial fibro-
sis is an early and progressive lesion ultimately associated
with UFF [8], the search for an effluent marker related to
membrane fibrosis process and exhibiting a good correl-
ation with ultrafiltration and FWT would be clinically im-
portant. Such a marker could timely detect peritoneal
membrane failure. Besides it should be desirable that such* Correspondence: anabernardo@portugalmail.pt
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unless otherwise stated.marker could signalize peritoneal membrane deterioration
even before clinically relevant UFF.
Hepatocyte growth factor (HGF) is known to play a
crucial role in the repairing process of tissues and pre-
venting organ fibrosis [9-12]. Yu et al. demonstrated, for
the first time, that human peritoneal mesothelial cells
constitutively synthesized HGF [13], and that treatment
of human peritoneal mesothelial cells with HGF blocks
high glucose-induced epithelial-to-mesenchymal transi-
tion (EMT). More recently, Ueno T, et al. showed that
HGF secreted by mesenchymal stem cells was implicated
in the inhibition of the transforming growth factor β1
signaling and ameliorated peritoneal fibrosis in an ex-
vivo study [12]. It is thus relevant to increase the know-
ledge on HGF clinical value, in patients under PD, as it
may possibly point to new diagnostic opportunities and
therapeutic avenues. Therefore clinical investigation
under this subject is mostly important and needed.
Impaired FWT is assumed to indicate a more severe
functional and structural membrane lesion due to
aquaporin disfunction or interstitial changes [6,14-16],al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tions between effluent HGF, ultrafiltration failure, FWT
and small-solute transport. For that reason, we per-
formed a clinical investigation in order to assess, in a
prevalent PD population, the relation between dialysate
HGF and the ultrafiltration profile, FWT quantification,
and small-solute transport.
Methods
Patients and procedures
This cross sectional study enrolled 68 patients of our
Unit. All the patients performed a 4-hour, 3.86% glucose
modified peritoneal equilibration test (PET) with total
temporary drainage at 60 minutes [“Two-in-one” proto-
col, as published before [7]]. This protocol allows free
water transport quantification, beyond a simple calcula-
tion of sodium sieving [7]. None of the patients had
peritonitis during the study or the preceding 6 weeks.
During the procedure, we used PD solutions low in glu-
cose degradation products, according to the individual
patient’s prescription. The volume of dialysis solution
was determined by weight, without flushing the system
and before filling the peritoneum. Blood and dialysate
samples (each approximately 10 mL) were taken at in-
stillation of the dialysate and after 60 and 240 minutes.
At 60 minutes, we performed an additional measure-
ment of UF by total drainage of the peritoneal cavity.
This drained volume was weighed and then immediately
reinfused. Finally, after 240 minutes, the peritoneal cav-
ity was drained and the volume obtained was weighed.
PETs with an ultrafiltered volume ≤ 400 mL/4 h were
considered to represent ultrafiltration failure (UFF).
All patients provided written informed consent for
participation, and the study was approved by the Ethics
Committee of St. António Hospital – Oporto Hospital
Center.
Measurements
Creatinine and sodium were measured both in plasma and
dialysate. For creatinine, the Jaffé compensated method
was used. The dialysate creatinine concentration was cor-
rected for interference by glucose according to our labora-
tory standards. Sodium was measured using indirect ion-
selective electrodes. Effluent samples taken at 4 hour were
immediately stored at −70°C, until they were used to
measure HGF, VEGF and CA125. Effluent CA125 was de-
termined with an electrochemiluminescence method on
an automated analyzer (COBAS e-411, Roche Diagnostics
GmbH). Effluent HGF and VEGF levels were determined
by ELISA technique according to the manufacturer’s
instructions (IBL – Immuno-Biological Laboratories Co.
Ltd). The intra and inter-assay variations were 8,8%% and
10,0%, respectively for HGF and 5,9%, and 9,4% for VEGF.
The sensitivity was 11 pg/mL for HGF and 1 pg/mL forVEGF. Both the assays are considered highly specific for
the cytokines, and no significant cross-reactivity was
observed.
Calculations
Patients were characterized by peritoneal transport status
as described by Twardowski et al. [17]. The MTACcreatinine
was calculated by the simplified Garred model [18].
FWT and UF through the small pores (SPUF) at 60 mi-
nutes were calculated as we previously described [7].
Using a simple algorithm, we also performed a correction
for FWTas described by Venturoli and Rippe [19].
Statistical analysis
Except for time on PD, HGF, HGF/CA125 and VEGF/
CA125, all variables had normal distribution. Results are
expressed as mean ± SD or as median and interquartile
range.
Pearson correlation analysis was used in order to ex-
plore possible relations between HGF (with logarithmic
transformation) and ultrafiltration profile, FWT and
small-solute transport.
For comparison of small solute transport, water trans-
port pathways and effluent markers between patients
with and without ultrafiltration failure, Mann–Whitney
U test was used.
In order to study our patients ultrafiltration failure
profile we made a comparison of small solute transport,
water transport pathways and effluent markers between
patients with FWT ≤ 45% and D/PCreatinine ≥ 0.81 and pa-
tients without FWT compromise and non-fast transport
category, using Mann–Whitney U test.
Unpaired Student t-Test or Mann Whitney U-test to
compare patients with FWT ≤ 45% and FWT > 45%, as
appropriate, according to the variables involved.
Results
Solute, fluid transport parameters and concentration of
cytokines in dialysate
Table 1 summarizes the peritoneal transport characteristics
evaluated with a combined (“two-in-one”) PET performed
in 68 study patients [35 men; mean age: 50 ± 14 years; 14
patients were diabetic; 16 were anuric; 36 were on APD;
PD vintage 18.7 ± 23.5 months (range 1 – 121 months)].
According to small solute transport characteristics, 1 (1.5%)
patient was classified as slow transporter (D/PCreatinine ≤
0,49), 10 (14.7%) as slow-average (0,50 ≤D/PCreatinine ≤
0.64), 41 (60.3%) as fast-average (0,65 ≤D/PCreatinine ≤ 0.80),
and 16 (23.5%) as fast transporters (D/PCreatinine ≥ 0,81).
Concerning water transport pathways, FWT accounted for
37.15% of the UF at 60 minutes, and once corrected (for so-
dium diffusion, cumulative UF volume through the large
pores, and cumulative lymphatic absorption at 60 minutes),
its contribution increased to a mean value of 45.46%.
Table 1 Peritoneal transport characteristics and effluent
cytokines in 68 stable patients assessed during a 4-hour,
3.86% glucose peritoneal equilibration test with temporary
drainage at 60 minutes
Variable Mean ± SD Median (IQR 25%-75%)
Total UF at 4 h (mL) 669,12 ± 226,76
SPUF (mL) 323,36 ± 129,34
FWT (mL) 183,26 ± 63,02
FWTcorrected(mL) 224,12 ± 66,51
%FWT 37,15 ± 11,79
%FWTcorrected 45,46 ± 11,11
D/P Creatinine 0,76 ± 0,12
MTAC Creatinine (mL/min) 11,32 ± 7,14
Effluent HGF (pg/mL) 77,17 (68,83 – 94,31)
Effluent VEGF (pg/mL) 13,96 ± 4,92
CA125 (U/mL) 19,57 ± 11,31
SD = standard deviation; UF = ultrafiltration; SPUF = UF through the small pores at
60 minutes; FWT = free water transport at 60 minutes; FWTcorrected = FWT with an
algorithm correction according to Venturoli and Rippe [16]; MTAC=mass transfer
area coefficient; D/P = dialysate-to-plasma ratio; HGF = hepatocyte growth factor;
VEGF = vascular endothelial growth factor; CA 125 = cancer antigen 125.
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HGF measured in the effluent significantly correlated
with total ultrafiltration at a 4 h, 3.86% glucose PET
(r = −0.358, p = 0.003), with FWT (r = −0.407, p = 0.001)
and MTACcreatinine (r = 0.355, p = 0.003). These correla-
tions were even stronger when we focused the analysis in
patients with ultrafiltration failure (Figures 1A,B,C). In
those patients, HGF exhibited a strong negative correl-
ation with total ultrafiltration and FWT (r = −0.802, p =
0.009 and r = −0.690, p = 0.04, respectively) and a strongFigure 1 HGF correlations with ultrafiltration, FWT and small-solute tr
(HGF) and total ultrafiltration at a 4 h, 3.86% glucose PET (UF240), in patien
correlation between effluent hepatocyte growth factor (HGF) and FWT corr
ultrafiltration failure (Pearson r = −0.690, p =0.04); (C) correlation between e
area coefficient (MTACcreatinine), in patients with ultrafiltration failure (Pearsopositive correlation with MTACcreatinine (r = 0.747, p =
0.021). No correlation was found between dialysate HGF
concentration and small pore water transport (neither in
global population, nor in the UFF group).
Patients with ultrafiltration failure compared with stable
patients
Among the 68 study patients, 9 (13.2%) had UFF (total
UF ≤ 400 mL/4 h). Although not statistically significant,
patients with UFF had been on PD for a longer time, had
higher D/Pcreatinine and MTACcreatinine(Table 2). HGF con-
centration was significant higher in patients with UFF
(median 103.0 pg/mL IQR [79.8–110.8]) compared with
stable patients (median 77.1 pg/mL IQR [68.1–92.6], p =
0.018). Although not statistically significant, patients with
UFF had also a higher ratio HGF/CA125 (Table 2).
Ultrafiltration failure profile
From the 9 patients with UFF, 3 had a more severe profile
characterized by FWT compromise (FWT ≤45%) and in-
creased (D/Pcreatinine ≥ 0,81). Those patients had significant
lower ultrafiltration volume at a 4 h PET (166.7 ± 57.4 mL
vs 375.0 ± 41.8 mL, p = 0.024), lower FWT quantification
(128.67 ± 26.50 mL vs 183.5 ± 12.14 mL, p = 0.024) and
higher MTACcreatinine (25.40 ± 2.63 mL/min vs 9.62 ±
2.45 mL/min, p = 0.024) (Figure 2A,B,C). Although not sta-
tistically significant, patients with the more severe UFF pro-
file had also higher values of HGF measured in the effluent
(104.3 pg/mL vs 88.94 pg/mL, p = 0.085) (Figure 2D).
Tree other patients showed a less severe UFF profile,
with increased effective capillary surface but preserved
FWT (>45%). And still 3 incident patients (3 – 6 months
on PD), were average transporters with preserved FWT,
in whom higher lymphatic absorption was by exclusion
presumed.ansport. (A) Correlation between effluent hepatocyte growth factor
ts with ultrafiltration failure (Pearson r = −0.802, p = 0.009); (B)
ected according to Venturoli and Rippe [16], in patients with
ffluent hepatocyte growth factor (HGF) and creatinine mass transfer
n r = 0.747, p = 0.021).
Table 2 Comparison of small solute transport, water
transport pathways and effluent markers between
patients with and without ultrafiltration failure
Patients with UFF
Mean ± SD Median
(IQR 25-75%)
Patients without UFF
Mean ± SD Median
(IQR 25-75%)
Patients (n) 9 59
Time on PD (months) 6.0 (4.0 – 35.5) 7.0 (4.0 – 27.0)
Total UF at 4 hour (mL) 305.56 ± 113.04a 724.58 ± 184.38a
SPUF (mL) 192.89 ± 59.41a 343.27 ± 125.68a
FWT (mL) 134.89 ± 35.07b 190.64 ± 63.25b
FWTcorrected(mL) 165.22 ± 31.93
c 233.10 ± 65.95c
%FWT 41.87 ± 13.07 36.43 ± 11. 53
%FWTcorrected 51.16 ± 12.29 44.59 ± 10.77
D/P Creatinine 0.81 ± 0.12 0.75 ± 0.11
MTAC Creatinine (mL/min) 14.88 ± 8.23 10.78 ± 6.87
Effluent HGF (pg/mL) 103.01 (79.83 – 110.78)d 77.07 (68.05 – 92.58)d
Effluent VEGF (pg/mL) 15.10 ± 5.68 13.79 ± 4.82
CA125 (U/mL) 24.63 ± 19.63 18.89 ± 9.75
HGF/CA125 (pg/U) 6.22 (2.28 – 8.27) 4.64 (3.30 – 6.36)
VEGF/CA125 (pg/U) 0.70 (0.53 – 1.39) 0.76 (0.54 – 1.08)
SD = standard deviation; UF = ultrafiltration; SPUF = UF through the small pores at
60 minutes; FWT = free water transport at 60 minutes; FWTcorrected = FWT with an
algorithm correction according to Venturoli and Rippe [16]; MTAC=mass transfer
area coefficient; D/P = dialysate-to-plasma ratio; HGF = hepatocyte growth factor;
VEGF = vascular endothelial growth factor; CA 125 = cancer antigen 125.
aMann–Whitney U test p <0.0001, comparing patients with and without
ultrafiltration failure.
bMann–Whitney U test p = 0.006, comparing patients with and without
ultrafiltration failure.
cMann–Whitney U test p = 0.002, comparing patients with and without
ultrafiltration failure.
dMann–Whitney U test p = 0.018, comparing patients with and without
ultrafiltration failure.
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From the 59 studied patients without UFF, 33 had a
FWT ≤45%. Those patients had a mean UF volume at 4 h
PET equivalent to patients with FWT > 45% (Table 3). Al-
though not statistically different, patients with FWT ≤ 45%
had higher effluent HGF, when compared with patients
with FWT> 45%. In spite of higher effluent HGF concen-
tration, the HGF/CA125 ratio was significantly lower in
patients without UFF and FWT ≤45% compared with pa-
tients without UFF and FWT >45% (3.65 IQR [ 2.96-5.60]
vs 5.19 IQR 4.02-8.37], p = 0.014).
Discussion
To our knowledge, the present study is the first to report
a clinical significant relation between HGF measured in
the effluent and ultrafiltration profile, FWT quantifica-
tion and small-solute transport in peritoneal dialysis pa-
tients. Since HGF is involved in the process of peritoneal
submesothelial fibrosis [12,13], this study also suggest
some structural-functional correlations.Although impaired FWT is frequently associated to
aquaporin dysfunction, several studies provided indirect
evidence that FWT can also be impaired in situations of
decreased peritoneal water permeability due to interstitial
changes, especially in long term patients [6]. Simulations of
osmotic ultrafiltration failure in CAPD using a serial three-
pore membrane/fiber matrix model [14] documented the
uncoupling of small solute transport from LpS in computer
simulations of UFF, whenever changes both in vasculature
and in interstitium are taken into account, supporting fur-
ther the role of the peritoneal membrane interstitium in
fluid transport. Moreover, Devuyst and Rippe stated in a
recent review [16] that reduced LpS in long-term PD has
been attributed to reductions in AQP1-meditated water
transport, but it might also be the result of a combination
of increased vascularization and fibrotic scar tissue in the
peritoneum.
When we analyze the reasons for UFF in our study we
distinguish 3 groups of patients. Three had a more se-
vere profile characterized by FWT compromise (FWT
≤45%) on top of increased effective capillary surface, also
with higher values of effluent HGF. Three patients pre-
sented an increased effective capillary surface but FWT
was not impaired. Another 3 incident patients were aver-
age transporters with normal FWT. A high effective
lymphatic absorption rate could be the reason for UFF
in those incident patients since high lymphatic absorp-
tion is recognized to be mostly a cause of inherent UFF
[5]. This variability in UFF patterns that we found was
also documented by Waniewsky et al. [15] that recog-
nized that UFF due to high peritoneal absorption could
be associated with normal or decrease fractional contri-
bution by transcellular pores to hydraulic conductivity.
It is noteworthy that mean HGF in those 3 patients
(with a functional UFF) was significantly lower com-
pared with the 3 patients that had impaired FWT [77.84
(67.9 – 79.8) vs 104.3 (103.7 – 147.16), p = 0.05].
In contrast with previous studies [4,6,20], MTACcreatinine
was higher but not statistically different between patients
with and without UFF. This is due to the presence of
many incident fast transporters (mean time on PD 6 ±
4 months) in the non UFF group.
Report and interpretation of causes of UFF as well as
absolute and fractional FWT may vary according to the
PD vintage. Our results are in accordance with Parikova
et al., [6] that documented an early stage UFF associated
with decrease of absolute FWT dependent on increased
effective capillary surface without significant decrease of
FWT contribution, while later the loss of osmotic con-
ductance to glucose lead to a significant decrease of
FWT fraction. In fact, all 9 patients with UFF had a sig-
nificant decrease in absolute FWT compared with pa-
tients without UFF, but only 3 had a reduction in FWT
contribution to 60 minutes ultrafiltration.
Figure 2 Ultrafiltration failure profile. Comparison within patients with UFF, between 6 patients with non compromised FWT and non fast
transporters versus 3 patients with FWT≤ 45% and fast transporters: (A) Total ultrafiltration at a 4 h, 3.86% glucose PET (375.0 ± 41.83 mL vs
166.67 ± 57.74 mL, p = 0.024). (B) FWT quantification at 60 minutes in a 4 h, 3.86% glucose PET (183.5 ± 12.14 mL vs 128.67 ± 26.50 mL, p = 0.024)
(C) MTACcreatinine (9.62 ± 2.45 mL/min vs 25.40 ± 2.63 mL/min, p = 0.024). (D) Effluent Hepatocyte Growth Factor (88.94 pg/mL vs 104.3 pg/mL,
p = 0.085). Box plot representation: 75% percentile, 25% percentile, median, and maximum and minimum values.
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the recent report from Nakamura S. et al. [21]. Those au-
thors studied focal HGF expression in peritoneum biop-
sies of a small number of peritoneal dialysis patients, with
and without UFF. Although they did not measure dialysate
HGF concentration, they demonstrated an increased ex-
pression of HGF in peritoneal tissues of CAPD patients
with low ultrafiltration capacity compared with those with
a normal ultrafiltration profile. Given the already men-
tioned protective effects of HGF on peritoneal fibrosis
[11-13], we hypothesized that the increased peritoneal
HGF expression demonstrated by Nakamura S. et al. [21],
and the higher dialysate HGF concentration that we
found in our patients with UFF, can be seen as a react-
ive mechanism to peritoneal membrane lesion. This isalso supported by the fact that patients with more se-
vere forms of UFF (with FWT compromise besides an
increase in small-solute transport), presented higher di-
alysate HGF concentration.
The effluent HGF concentration on patients under PD
was addressed, until now, by one single clinical study [22].
However, Mizuiri S et al. [22], only compared dialysate
HGF concentration according to small solute transport
status, and found that fast transporters had higher effluent
HGF concentration compared with others small solute
transport categories, which we also reproduce (data not
shown). Unfortunately such study gave no information
about UFF or water transport pathways quantification.
As others [23] we also found significantly higher dialys-
ate VEGF concentration in fast transporters compared
Table 3 FWT profile in patients without UFF: comparison
of small solute transport, water transport pathways and
effluent markers between patients with FWT ≤ 45% and
FWT > 45%
Patients without ultrafiltration failure
Patients with FWT≤ 45%
Mean±SD Median
(IQR 25-75%)
Patients with FWT>45%
Mean±SD Median
(IQR 25-75%)
Patients (n) 33 26
Time on PD
(months)
6.0 (4.0 – 19.0) 8.5 (5.0 – 30.25)
Total UF at 4 hour
(mL)
739.39 ± 210.56 705.77 ± 146.51
SPUF (mL) 412.9 ± 108.54a 254.81 ± 83.74a
FWT (mL) 173.42 ± 60.43b 212.50 ± 60.98b
FWTcorrected(mL) 221.51 ± 66.11 247.81 ± 63.97
%FWT 29.10 ± 6.50a 45.74 ± 9. 66a
%FWTcorrected 37.56 ± 5.62
a 53.52 ± 8.96a
D/P Creatinine 0.76 ± 0.08 0.73 ± 0.14
MTAC Creatinine
(mL/min)
10.45 ± 5.14 11.20 ± 8.69
Effluent HGF
(pg/mL)
77.17 (68.42 – 93.89) 75.89 (66.47 – 86.51)
Effluent VEGF
(pg/mL)
14.19 ± 4.96 13.28 ± 4.68
CA125 (U/mL) 22.28 ± 10.90c 14.56 ± 5.82c
HGF/CA125 (pg/U) 3.65 (2.96 – 5.60) d 5.19 (4.02 – 8.37) d
VEGF/CA125 (pg/U) 0.68 (0.51 – 0.90) 0.89 (0.67 – 1.29)
Variables presented as mean ± SD or median (interquartile range) accordingly. SD
= standard deviation; UF = ultrafiltration; SPUF = UF through the small pores at
60 minutes; FWT = free water transport at 60 minutes; FWTcorrected = FWT with an
algorithm correction according to Venturoli and Rippe [16]; MTAC=mass transfer
area coefficient; D/P = dialysate-to-plasma ratio; HGF = hepatocyte growth factor;
VEGF = vascular endothelial growth factor; CA 125 = cancer antigen 125.
a) T-test p <0.0001, comparing patients with FWT ≤ 45% and FWT > 45%.
b) T-test p = 0.017, comparing patients with FWT ≤ 45% and FWT > 45%.
c) T-test p = 0.001, comparing patients with FWT ≤ 45% and FWT > 45%.
d) Mann–Whitney U test p = 0.014, comparing patients with FWT ≤ 45%
and FWT > 45%.
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remains uncertain if this increase in VEGF production cor-
responds to an increased production of intraperitoneal
vasoactive substances, as might occur in incident fast trans-
porters, or if it is the result of epithelial-to-mesenchymal
transition, dialysate VEGF was not discriminative of UFF.
On the contrary, effluent HGF was informative not only
about UFF but also highlighted more severe UFF profile,
with FWTcompromise.
We are aware that the mass of mesothelial cells could
affect the levels of intraperitoneal growth factors in PD pa-
tients. Although there are some controversies about the
use of CA125 as an index of mesothelial cells mass or their
functional properties [24-26], we also documented a higher
HGF/CA125 ratio in UFF patients compared with stablepatients, indicating a reactive increased HGF production
beyond that we would expect for the mesothelial cell mass.
Since there are no clinical studies that had examined
plasma and effluent HGF, and we found a correlation with
small-solute transport, we might question whether effluent
HGF concentration could depend on plasma HGF levels.
We think that this is not plausible for various reasons.
First, the peritoneal permeability is expected to be poor,
since HGF is a heterodimeric molecule composed of a 69
KDa alpha subunit and a 34 KDa beta subunit. Second
and mostly important, human peritoneal cells constitu-
tively synthesized HGF [13]. For these reasons, we believe
that the HGF protein detected in the effluent is locally
produced.
The use of effluent biomarkers as an early sign of peri-
toneal membrane alterations is currently under debate
[27-29] specially because clinical factors cannot give an
accurate individual prediction for EPS [30].
In a very recent report [27], MCP-1, IL-6 and CCL15
were found at higher levels in the dialysate of patients who
subsequently developed EPS. However, by logistic regres-
sion analysis, these cytokines did not improve prediction
of future EPS above known clinical factors, as PD vintage
and peritoneal small solute transport. On the contrary,
Sampimon et al. [28] concluded that dialysate appearance
rate of CA125 and IL-6 combined was potentially useful
for an early diagnosis of EPS. None of these studies ex-
plored the associations between the cytokines measured in
the dialysate and ultrafiltration or water transport path-
ways in a peritoneal equilibration test. These would be of
great importance as we know that in the 2 years that pre-
cede an EPS diagnosis, a proportion of patients with EPS
present an uncoupling between the membrane ultrafiltra-
tion capacity and the peritoneal membrane small solute
transport [30]. This fact gives even more strength to the
necessity of finding a biomarker that correlates both with
ultrafiltration and with water transport pathways, and not
only to the membrane small solute transport status. HGF
can be easily measured, without specific preparation of the
dialysate sample, by commercially available highly specific
assay (IBL-Immuno-Biological Laboratories Co.Ltd), with
acceptable inter-assay variability (10%); it is constitutively
synthesized by human peritoneal mesothelial cells, blocks
high glucose-induced epithelial-to-mesenchymal transition
(EMT) and was implicated in the inhibition of the trans-
forming growth factor β1 signaling, ameliorating peri-
toneal fibrosis in an ex-vivo study [13]. According to our
present investigation, dialysate HGF concentration in-
creases as ultrafiltration decreases in a 4-hour, 3,86% glu-
cose PET. The fact that dialysate HGF concentration is
even higher among patients with FWT compromise and
fast transport status increases the likelihood of effluent
HGF concentration being related with peritoneal deterior-
ation, as a reactive repairing mechanism, and not with a
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lymphatic absorption rate, hardly measurable in clinic.
In this study we reported a mean FWTcorrected fraction
of 45%, which is in line with our previous studies [7], and
with the FWT fraction reported by La Milia [31]. A
FWT ≤ 45% is clinical relevant in patients with UFF, since
it may signalize aquaporin dysfunction or interstitial fibro-
sis with glucose osmotic conductance compromise, with
important repercussions for PD prescription. However,
there is no knowledge yet about the clinical value of FWT
fraction on patients without UFF. We think that this is an-
other relevant aspect of our investigation: although we did
find that patients without UFF but with FWT fraction
≤45% had higher dialysate HGF concentration compared
with patients with preserved FWT fraction, the first group
had a significant lower mean value of HGF/CA125 ratio
compared with the second one. This trend is completely
different from that we observed in patients with UFF, in
whom we found a higher HGF/CA125 ratio. We hypothe-
sized that this may represent an intermediate level of peri-
toneal dysfunction, where the patient may already have
interstitial changes that lead to a reactive increase in HGF
production, while not severe enough to present as UFF. At
this point, those patients may still have a preserved meso-
thelial cell mass which explains the lower HGF/CA125 ra-
tio that we found in this group. Aging, uremia, diabetes are
indeed often associated with membrane changes already at
PD start possibly justifying in some patients selective FWT
compromise in absence of clinically relevant UFF [32-35].
Our study is limited by its cross sectional design and
small number of patients with UFF. A longitudinal study
is being conducted in order to document the dynamic
profile of HGF production and its relationship with peri-
toneal membrane water transport changes. More studies
are needed to increase the knowledge on HGF clinical
value, in patients under PD, as it may possibly point to
new diagnostic opportunities and therapeutic avenues in
the ultrafiltration failure field.
Conclusions
Since HGF ameliorated peritoneal fibrosis in an ex-vivo
study [12], a clinical study as ours looks opportune. Our
results demonstrated, for the first time, that dialysate
HGF concentration is significantly higher among pa-
tients with ultrafiltration failure, specially if free water
transport is impaired, being an useful marker of progres-
sive peritoneal deterioration.
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